0 results available. Select is focused ,type to refine list, press Down to open the menu,
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform ...
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EV / EBITDA in the valuation category include:
LTM EBITDA Multiple is defined as:
EBITDA Multiple = Enterprise Value / LTM EBITDA
Applying this formula, Insulet’s EV/EBITDA Ratio is calculated below:
Enterprise Value [ $19.118 B ]
(/) EBITDA [ $389.7 M ]
(=) EV/EBITDA Ratio [ 49.1x ]
The tables below summarizes the trend in Insulet’s EV/EBITDA Ratio over the last five years:
| Date | Enterprise Value | EBITDA | EV/EBITDA Ratio |
|---|---|---|---|
| 2020-12-31 | $16.883 B | $115.7 M | 145.9 |
| 2021-12-31 | $18.779 B | $137.2 M | 136.9 |
| 2022-12-31 | $21.13 B | $189.8 M | 111.3 |
| 2023-12-31 | $15.92 B | $190.4 M | 83.6 |
| 2024-12-31 | $19.118 B | $389.7 M | 49.1 |
EBITDA Multiple, Enterprise Value / EBITDA, or EV / EBITDA measures the dollars in Enterprise Value for each dollar of EBITDA.
EBITDA is used in the denominator since it is capital structure neutral and can be used to compare companies with different levels of debt (See EBITDA for benefits). We use Enterprise Value as the numerator to consider the claims on EBITDA of both debt and equity holders.
Strong revenue and EBITDA growth are highly correlated with higher EBITDA Multiples.
Read more about enterprise value (ev) and ebitda